VALENCIA, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host
an analyst call for the investment community to learn about the company's general commercialization strategy in the US for
Afrezza® (insulin human) Inhalation Powder. MannKind has recently assumed responsibility for the worldwide development
and commercialization of Afrezza from Sanofi and will begin to distribute Afrezza in the third quarter. Until that time, Sanofi
will continue to distribute Afrezza from its existing inventory of product.
To participate in the live call by telephone, please dial (888) 224-7957 or (303) 223-4394 and use the participant passcode: